The Evidence-based Approach to Neurologic Emergencies: Part II: Hemorrhagic Stroke and Traumatic Brain Injury - Emergency Medicine Reports - April 22, 2012

Target Audience:

This CME activity is intended for emergency physicians and family physicians.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.3 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
This activity is approved by the American College of Emergency Physicians for 2.25 hours of ACEP Category 1 credits.
 
Emergency Medicine Reports has been reviewed and is acceptable for up to 1.5 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 01/01/12. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of each issue.

Faculty

Editors
J. Stephan Stapczynski, MD
Chair
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Sandra M. Schneider, MD
Professor, Department of Emergency Medicine
University of Rochester School of Medicine
Rochester, New York

CME Question Reviewer
Roger Farel, MD
Retired
Newport Beach, CA

Executive Editor
Shelley Mark

Managing Editor
Leslie Hamlin

Author
Ademola Adewale, MD, FAAEM
Assistant Professor of Emergency Medicine
Florida State University College of Medicine
Director of Research and Medical Simulation
Florida Hospital Emergency Medicine Residency Program
Orlando, FL

Peer Reviewer
Bentley J. Bobrow, MD
Associate Professor of Emergency Medicine
Emergency Medicine Department
Maricopa Medical Center
Phoenix, AZ

Subjects:

  • The Evidence-based Approach to Neurologic Emergencies: Part II: Hemorrhagic Stroke and Traumatic Brain Injury

Objectives:

  • Recognize or increase index of suspicion for specific conditions
  • State the epidemiology, etiology, pathophysiology, and clinical features of the entity discussed
  • Apply state-of-the-art diagnostic and therapeutic techniques (including the implications of pharmaceutical therapy discussed) to patients with the particular medical problems discussed.
  • Discuss the differential diagnosis of the entity discussed.
  • Explain both likely and rare complications that may occur.

Financial Disclosure:

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Roger Farel, MD (CME question reviewer) owns stock in Johnson& Johnson. J. Stephan Stapczynski, MD (editor) owns stock in Bristol Myers Squibb. Sandra M. Schneider, MD (editor), Ademola Adewale, MD (author), Bentley J. Bobrow, MD (peer reviewer), Shelley Mark (executive editor), and Leslie Hamlin (managing editor) report no financial relationships with companies related to the field of study covered by this CME activity

Copyright 2012 AHC Media LLC. All rights reserved.